Botaluma (botulinum toxin type A) / ATGC Co, Huadong Medicine - LARVOL DELTA

ATGC wins MFDS nod for BTX Injection (Korea Biomedical Review) - "ATGC, a Korean biopharmaceutical company, said Tuesday that Botaluma Injection, its new botulinum toxin (BTX) product, received marketing approval from the Ministry of Food and Drug Safety (MFDS). Botaluma Injection is a pure-form botulinum toxin type A that contains only the 150 kDa core neurotoxin protein, excluding complexing non-toxic proteins....It is designed to minimize immunogenicity by eliminating accessory proteins that can lead to antibody formation....The approval marks the third pure-form botulinum toxin authorized in Korea and the fourth globally."

Korea approval • Dermatology

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: ATGC Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: ATGC Co., Ltd.

New P3 trial

A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines (clinicaltrials.gov) - P1/2; N=60; Completed; Sponsor: ATGC Co., Ltd.; Active, not recruiting ➔ Completed

Clinical • Trial completion